: CytomX shares surge more than 50% on Moderna partnership


CytomX Therapeutics Inc. CTMX, +7.19% shares soared more than 50% in the extended session Thursday after the small biotech company announced a partnership with Moderna Inc. MRNA, -2.17% CytomX shares were last up 57% after hours, following a 7.2% rise to close the regular session at $1.79. Under the agreement, CytomX gets a $35 million up-front payment, and is eligible for up to $1.2 billion in additional payments to research and develop “messenger RNA-based conditionally activated therapeutics” with Moderna. The company also reported “encouraging clinical activity” in its CX-2029 clinical trials in partnership with AbbVie Inc. ABBV, -0.12%  

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: Looking for clues about iPhone supply? Ask AT&T, Verizon and T-Mobile
Next articleVince McMahon plans to return to WWE and sell the company: report


Please enter your comment!
Please enter your name here